{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:24:12Z","timestamp":1783596252241,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Vancomycin-resistant enterococci (VRE) Enterococcus faecalis (E. faecalis) remains largely ampicillin-susceptible, yet broad-spectrum agents are frequently used empirically (i.e., daptomycin and linezolid). Despite its frequent susceptibility to ampicillin, VRE E. faecalis is often managed with broad-spectrum antimicrobials, raising concerns about overtreatment and antimicrobial stewardship. Resistance mechanisms vary, with vancomycin resistance mediated by vanA\/vanB operons and beta-lactams by altered penicillin binding proteins. These distinct mechanisms help explain why VRE E. faecalis isolates may remain susceptible to ampicillin, supporting its potential use in clinical isolates. This study aims to describe the antibacterial susceptibility results of Enterococcus faecalis VRE and assess antibiotics use in clinical settings in a tertiary medical center. Methods: This was a single-center, retrospective, descriptive study of hospitalized and outpatient adults with Enterococcus faecalis VRE isolates identified between 1 June 2018 and 15 March 2025. We excluded individuals with concomitant non-Enterococcus faecalis VRE infections and those aged &lt;18 years. Vancomycin resistance was defined by a minimum inhibitory concentration of &gt;32 mcg\/mL per the 35th edition of the Clinical and Laboratory Standards Institution breakpoints. Results: A total of 337 patients were screened; 114 met inclusion criteria. The cohort was 54% female, 50% Black, and 48% White, with 54% having hypertension, 36% diabetes, and 19% a history of multidrug-resistant organism carriage. The most common source of infection was urinary (67%), followed by skin and soft tissue infections and bone\/joint infections (11% each). All isolates were vancomycin-resistant; 82% were susceptible to ampicillin, 84% to nitrofurantoin, 61% to daptomycin, and 70% to linezolid. Antimicrobial regimens varied, with daptomycin being the most used agent (19%). No patients in the aminopenicillin group experienced 30-day mortality, whereas two patients (3%) in the non-aminopenicillin group died within 30 days. Acute kidney injury occurred in four patients (29%) in the aminopenicillin group compared with four patients (7%) in the non-aminopenicillin group, representing a significantly higher incidence in the aminopenicillin group (p = 0.037). However, myalgia, elevated creatine phosphokinase, and thrombocytopenia were more common in the non-aminopenicillin group. Conclusions: Despite higher susceptibility to ampicillin and nitrofurantoin, daptomycin was the most used agent for VRE E. faecalis infections. These findings highlight a need for improved antimicrobial stewardship and further clinical studies to guide optimal therapy.<\/jats:p>","DOI":"10.3390\/antibiotics15070672","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:16:22Z","timestamp":1783592182000},"page":"672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial Stewardship in Vancomycin-Resistant Enterococcus faecalis: Clinical Study Evaluating Antimicrobial Susceptibility Patterns and Antibacterial Regimens"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1579-6351","authenticated-orcid":false,"given":"Samantha A.","family":"Tolbert","sequence":"first","affiliation":[{"name":"Ochsner LSU Health Shreveport\u2014Academic Medical Center, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-7784","authenticated-orcid":false,"given":"Mollie V.","family":"Day","sequence":"additional","affiliation":[{"name":"Ochsner LSU Health Shreveport\u2014Academic Medical Center, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Arif","sequence":"additional","affiliation":[{"name":"Ochsner LSU Health Shreveport\u2014Academic Medical Center, Shreveport, LA 71103, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3824-8744","authenticated-orcid":false,"given":"Preston H.","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5524-4237","authenticated-orcid":false,"given":"Destyn","family":"Dicharry","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Malek","sequence":"additional","affiliation":[{"name":"Ochsner LSU Health Shreveport\u2014Academic Medical Center, Shreveport, LA 71103, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S54125","article-title":"Vancomycin-Resistant Enterococcal Infections: Epidemiology, Clinical Manifestations, and Optimal Management","volume":"8","author":"Crank","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin-Resistant Enterococcal Infections","volume":"342","author":"Murray","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (2026, January 10). Antimicrobial Resistance Threats in the United States, 2021\u20132022. Antimicrobial Resistance. Published 16 July 2024, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/update-2022.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00058-18","DOI":"10.1128\/CMR.00058-18","article-title":"The Enterococcus: A Model of Adaptability to Its Environment","volume":"32","author":"Rice","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/civ449","article-title":"Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience","volume":"61","author":"McKinnell","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1128\/AAC.36.11.2355","article-title":"Beta-Lactamase-Producing Enterococci","volume":"36","author":"Murray","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","unstructured":"JMI Laboratories (2025, April 25). SENTRY Antimicrobial Surveillance Program. Available online: https:\/\/Sentry-Mvp.Jmilabs.Com\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1592\/phco.30.11.1136","article-title":"Vancomycin-Resistant Enterococcal Urinary Tract Infections","volume":"30","author":"Heintz","year":"2010","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e21200008","DOI":"10.14440\/bladder.2024.0016","article-title":"Oral Antimicrobial Options for Vancomycin-Resistant Enterococcus Isolates in Urine Culture","volume":"11","author":"Mohammed","year":"2024","journal-title":"Bladder"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2017.06.008","article-title":"Ampicillin for the Treatment of Complicated Urinary Tract Infections Caused by Vancomycin\u2013Resistant Enterococcus spp. (VRE): A Single-Center University Hospital Experience","volume":"51","author":"Shah","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","article-title":"Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America","volume":"68","author":"Nicolle","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2444495","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Trautner, B.W., Cort\u00e9s-Penfield, N.W., Gupta, K., Hirsch, E.B., Horstman, M., Moran, G.J., Colgan, R., O\u2019Horo, J.C., Ashraf, M.S., and Connolly, S. (2025). Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections\u2014Duration of Antibiotics for Complicated UTI. Clin. Infect. Dis., ciaf462.","DOI":"10.1093\/cid\/ciaf462"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1128\/AAC.01817-15","article-title":"Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections","volume":"59","author":"Cole","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC Guidelines for the Management of Endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e01050-25","DOI":"10.1128\/aac.01050-25","article-title":"Ceftobiprole Alone versus Ampicillin-Ceftriaxone against Borderline-Penicillin-Resistant, Ampicillin-Susceptible, and Vancomycin-Resistant Enterococcus Faecalis Isolates","volume":"70","author":"Funk","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice Guidelines for the Management of Bacterial Meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","unstructured":"CLSI (2025). M100-ED35:2025 Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [35th ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"dkag179","DOI":"10.1093\/jac\/dkag179","article-title":"High-Dose Daptomycin for the Treatment of Invasive Infections Due to Enterococcus Faecalis Isolates with Intermediate Susceptibility","volume":"81","author":"Drake","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","unstructured":"Python Software Foundation (Python, 2025). Python, version 4."},{"key":"ref_27","unstructured":"Google (2025, January 23). Google Colaboratory, 2017. Available online: https:\/\/colab.research.google.com."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:39:35Z","timestamp":1783593575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/7\/672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["antibiotics15070672"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15070672","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}